Samjin Nimodipine Tablet

Adult dose

Swallow without chewing with a small amount of liquid, with or without food. 1. Ischemic neurologic disorders due to cerebral vasospasm: After administering nimodipine injection for 5-14 days after hemorrhage, administer 60 milligrams of nimodipine per dose orally every 4 hours, 6 times daily for 7 days. 2. Cerebral dysfunction: Administer 30 milligrams of this medicine per dose 3 times daily. Maintain an interval of at least 4 hours between doses. Do not use the oral and injectable preparations concomitantly. Adjust the dose appropriately according to age and symptoms.

This medication should not be used in patients with known allergies to this drug or its components. It is safe not to administer to pregnant or potentially pregnant women and breastfeeding women. Patients with severely impaired liver function, such as those with cirrhosis, should not receive this medication as its effects may be excessive. Additionally, patients taking rifampicin or certain anticonvulsants (phenobarbital, phenytoin, carbamazepine) may experience reduced efficacy, so concurrent use is not recommended. This medication contains lactose, so it should not be given to patients with lactose intolerance or genetic lactose metabolic disorders. Caution is required when using this medication in patients with cerebral edema or increased intracranial pressure, as well as those with impaired liver or kidney function, due to the risk of side effects like hypotension, which may require dose adjustments. It should also be used cautiously in patients with hypotension. As this medication is metabolized by a specific enzyme (cytochrome P450 3A4) in the liver, drug interactions with other medications that inhibit or activate this enzyme may lead to changes in drug concentration, resulting in side effects or reduced efficacy. Dizziness can occur during treatment with this medication, so caution is necessary when driving or performing hazardous activities. Gastrointestinal symptoms such as nausea, gastrointestinal discomfort, constipation, or diarrhea may occur, and liver function test values may temporarily increase. Central nervous system symptoms may include headaches, dizziness, drowsiness, insomnia, and anxiety. Cardiovascular reactions have also been reported, including hypotension, arrhythmias, and edema. In the case of overdose, symptoms may include severe hypotension, arrhythmias, and nausea, and immediate discontinuation and medical attention are necessary. Safety during pregnancy has not been established, and since this medication can be transmitted through breast milk, it is advisable to avoid administration or to suspend breastfeeding if possible. The safety and efficacy in children have not been sufficiently studied. Elderly patients or those with compromised cardiac and renal function require careful observation and dose adjustments when using this medication. Taking this medication with grapefruit juice may increase blood concentration and risk of side effects, so grapefruit juice should be avoided.

• Nausea
• gastrointestinal disorders
• intestinal obstruction
• constipation
• diarrhea
• bloating
• elevated transaminases
• elevated alkaline phosphatase
• elevated gamma-GTP
• headache

This medication is sensitive to light and should be stored in a special container that does not allow light to enter. Additionally, it is best to store the medication at room temperature, avoiding extremely hot or cold locations.

Appearance

White to yellowish round film-coated tablet

Package unit

For domestic use - 500 tablets/bottle, For domestic use - 100 tablets/box [10 tablets/PTP*10], For export - 60 tablets/box [10 tablets/PTP*6], For export - 30 tablets/box [10 tablets/PTP*3]